Facebook
X
LinkedIn
ForwardClinical Multidisciplinary Hematology & Oncology: The 20th Annual Review - 2026
This course offers Live (in-person) and Livestream (virtual) attendance options
Course Directors: Allison C. Rosenthal, D.O. and Christina S. Wu, M.B., B.Ch., M.D.
Co-Course Directors: Carol P. Bryant, D.N.P., R.N., C.N.P., C.C.R.N. and Farah Raheem, Pharm. D., R.Ph.
April 17 - 19, 2026 - The Westin Kierland Resort & Spa - Scottsdale, Arizona
This course offers attendees a comprehensive update in the diagnosis and management of key diseases in hematology and medical oncology. Presentations provide updates on new data and best practices for physicians and the healthcare team. The format for this activity is didactic presentations followed by Q&A sessions. In person and virtual attendance will be offered. Continuing medical education credits will be offered for physicians, APPs, pharmacists, and nurses.
To see the course fee, please log in or create an account
| Registration Fee(s) | Live (in-person) On or Before December 12, 2025 | Live (in-person) After December 12, 2025 | Livestream (virtual) |
|---|---|---|---|
| M.D., D.O., Ph.D. | $950 | $1025 | $950 |
| Allied Health, NP, PA, Retirees | $750 | $825 | $750 |
Target Audience
This course is designed for physicians, advanced practice providers, pharmacists, and nurses interested in the diagnosis and treatment of patients with hematologic and oncologic disorders. Hospitalists, family medicine providers, general internists, or other healthcare professionals may benefit from this program.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify optimal treatment selection for relapsed, refractory acute myeloid leukemia patients
- Determine the optimal time to treat smoldering multiple myeloma
- Outline VTE prophylaxis and management
- Recognize that adjuvant immunotherapy can improve survival outcomes for patients with head/neck cancer.
- Review the pros/cons of perioperative immunotherapy for gastric cancer
- Review the pros/cons of neoadjuvant immunotherapy vs adjuvant immunotherapy and chemotherapy for dMMR stage III colon cancer.
- Discuss the role of neoadjuvant therapy in locally advanced lung cancer
- Determine how to de-escalate neoadjuvant therapy in breast cancer
Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.
Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review – 2026 | |
Friday, April 17, 2026 | |
6:00 AM | Registration, Breakfast and Exhibits |
7:00 AM | Welcome & Introductions |
Session I |
|
7:10 AM | Session I Pre-Test |
7:25 AM | Smoldering multiple myeloma – to treat or not to treat? |
7:45 AM | Multiple myeloma in 2026 – incorporating quadruple therapy and novel CELMoDs |
8:05 AM | Modern Front-line treatment DLBCL |
8:25 AM | CAR-T cell Therapy and Bispecifics: When and for Whom in the Community? |
8:45 AM | Q&A Panel Discussion Raphael Fonseca, M.D., TBD, Javier Munoz, M.D., M.B.A., Kharfan Dhabaja, M.D., M.B.A. |
9:05 AM | Session I Post-Test |
Refreshment Break and Exhibits | |
Session II |
|
9:40 AM | Session II Pre-Test |
9:55 AM | Targeted therapies for AML: FLT3 and Menin inhibitors for community clinicians |
10:15 AM | Sequencing therapies for low risk MDS: imetelstat, luspatercept, HMAs |
10:35 AM | MDS and AML: Risk stratification and Targeted therapy in an evolving landscape Lisa Z. Sproat, M.D. |
10:55 AM | Updates in MPNs |
11:15 AM | Q&A Panel Discussion |
11:35 AM | Session II Post-Test |
11:50 AM | Lunch |
Session III | Genitourinary cancers |
12:50 PM | Session III Pre-Test |
1:05 PM | Neoadjuvant therapy in bladder cancer |
1:25 PM | Treatment in locally advanced renal cell cancer |
1:45 PM | Updates on treatment of metastatic prostate cancer |
2:05 PM | Tumor board: PARP inhibitors in prostate cancer |
2:25 PM | Q&A Panel Discussion |
2:45 PM | Session III Post-Test |
3:00 PM | Break |
Session IV |
|
3:20 PM | Session IV Pre-Test |
3:35 PM | Ocular toxicities |
3:55 PM | Psychological Needs of the AYA Population |
4:15 PM | Beyond diabetes- Understanding cancer therapy induced hyperglycemia |
4:35 PM | Fertility Preservation in a Cancer Patient |
4:55 PM | Q&A Panel Discussion |
5:15 PM | Session IV Post-Test |
5:30 PM | Adjourn |
6:00 PM | Welcome Reception |
Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review – 2026 | |
Saturday April 18, 2026 | |
6:30 AM | Registration, Breakfast and Exhibits |
7:30 AM. | Announcements |
Session V | |
7:10 AM | Session V Pre-Test |
7:25 AM | Follicular lymphoma: When do you treat and with what? Early vs late relapse |
7:45 AM | Chronic Lymphocytic Leukemia (CLL): Sequencing Therapy in the BTK and BCL2 inhibitor era |
8:05 AM | Future of Radiation- When do we give carbon ion radiation? |
8:25 AM | Q&A Panel Discussion |
8:35 AM | Session V Post-Test |
8:45 AM | KEYNOTE SPEAKER- AI in Oncology- Transforming Cancer Care |
9:20 AM | Refreshment Break and Exhibits |
Session VI |
|
9:40 AM | Session VI Pre-Test |
9:55 AM | The Conundrums in managing Cancer-Associated Thrombosis |
10:15 AM | Immune Thrombocytopenia (ITP): What to do when steroids fail |
10:35 AM | Anemia in the Older Adult: What’s New, What’s Missed? |
10:55 AM | Benign vs Malignant: Interpreting Clonal Hematopoiesis (CHIP CCUS MDS) Abhishek A. Mangaonkar, M.B.B.S. |
11:15 AM | Q&A Panel Discussion |
11:35 AM | Session VI Post-Test |
11:50 AM | Lunch |
Session VII | Gastrointestinal cancer |
12:50 PM | Session VII Pre-Test |
1:05 PM | Is there a role for chemotherapy in dMMR stage 3 colon cancer? |
1:25 PM | Is there a role for immunotherapy in resectable esophageal cancer |
1:45 PM | KRAS inhibitors in GI cancers |
2:05 PM | Tumor board: Neoadjuvant therapy for locally advanced rectal cancer |
2:25 PM | Q&A Panel Discussion |
2:45 PM | Session VII Post-Test |
3:00 PM | Break |
Session VIII |
|
3:20 PM | Session VIII Pre-Test |
3:35 PM | Updates in metastatic GYN cancers -Immunotherapy and antibody-drug conjugates |
3:55 PM | Integrative Oncology- Myths and truths of febendazole, ivermectin, methylene blue, and other supplements |
4:15 PM | Structured exercise to reduce recurrence of colon cancer- the CHALLENGE study |
4:35 PM | Updates in Supportive care treatments |
4:55 PM | Q&A Panel Discussion |
5:15 PM | Session VIII Post-Test |
5:30 PM | Adjourn |
Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review – 2026 | |
Sunday April 19, 2026 | |
6:00 AM | Registration, Breakfast and Exhibits |
7:00 AM | Announcements |
Session IX | Breast cancer |
7:10 AM | Session IX Pre-Test |
7:25 AM | Treating HR+ metastatic breast cancer therapy, beyond first-line |
7:45 AM | De-escalating treatment in early stage HER2 + breast cancer |
8:05 AM | Debate: MRD testing is important in breast cancer care |
8:25 AM | Personalized treatment in early-stage triple negative breast cancer |
8:45 AM | Q&A Panel Discussion |
9:05 AM | Session IX Post-Test |
9:20 AM | Refreshment Break and Exhibits |
Session X | Lung and Head/Neck Cancers |
9:40 AM | Session X Pre-Test |
9:55 AM | Adjuvant therapy in Head/Neck cancers |
10:15 AM | Updates on treatment in small cell lung cancer |
10:35 AM | Updates on Targeted Therapies in lung cancer |
10:55 AM | Tumor board: Peri-operative systemic therapy for lung cancer |
11:15 AM | Q&A Panel Discussion |
11:35 AM | Session X Post-Test |
11:50 AM | Closing Comments Adjourn |
All travel and lodging expenses are the sole responsibility of the individual registrant.
Travel
AIRPORTS
Phoenix Sky Harbor International Airport (PHX) – 8 miles or approximately 20 minutes to hotel
RECREATION / LEISURE ACTIVITIES
Click here for recreation or leisure activities.
Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Statement(s):
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 21.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.
AAPA
Mayo Clinic College of Medicine and Science has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 21.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation
ACPE
Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 21.25 ACPE Knowledge contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity.
UAN Number: JA0000238-0000-26-005-L01-P
ANCC
Mayo Clinic College of Medicine and Science designates this activity for a maximum of 21.25 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
AOA
The American Osteopathic Association designates this program for a maximum of 21.25 AOA Category 2-A credits.
Other Healthcare Professionals:
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
| Day | Credit(s) |
|---|---|
| Friday | 8.50 |
| Saturday | 8.50 |
| Sunday | 4.25 |
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
Available Credit
- 21.25 AAPA Category 1
- 21.25 ACPE
- 21.25 AMA PRA Category 1 Credit™
- 21.25 ANCC
- 21.25 AOA Category 2-A
- 21.25 Attendance
We are excited to share that the Clinical Multidisciplinary Hematology & Oncology: The 20th Annual Review - 2026 has commercial support offerings, including a variety of sponsorship opportunities! Please check out our comprehensive prospectus.
If you are interested in Exhibiting/Sponsoring, please complete the Letter of Agreement.
To pay for your Exhibit/Sponorship using card click here.
If you have additional questions, please contact: Morgan Gish
This course offers the unique opportunity for sponsorship opportunities, including the ability to interact with healthcare providers and highlight their products and services through an exhibit. For more information, please contact Susan Reigel or Morgan Gish
To see the course fee, please log in or create an account
| Registration Fee(s) | Live (in-person) On or Before December 12, 2025 | Live (in-person) After December 12, 2025 | Livestream (virtual) |
|---|---|---|---|
| M.D., D.O., Ph.D. | $950 | $1025 | $950 |
| Allied Health, NP, PA, Retirees | $750 | $825 | $750 |
Please update your profile to let us know if you have dietary restrictions or access requirements.
To claim credit for livestream participation in this course, learners must view the content during the hours posted for the live activity. This course is not approved for on-demand delivery.
Commitment to Belonging and Inclusion
Mayo Clinic School of Continuous Professional Development (MCSCPD) strives to foster a learning environment in which all individuals are valued, allowing all to achieve their fullest potential.
Cancellation and Refund Policy
View Cancellation and Refund Policy
All requests must be submitted in writing using the Contact Us Form.
Any use of this site constitutes your agreement to the Terms and Conditions of Registration.